Please login to the form below

Not currently logged in
Email:
Password:

gouty arthritis

This page shows the latest gouty arthritis news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

Ilaris is an interleukin-1 beta inhibitor and has been on sale since 2009, gradually picking up approvals for a range of inflammatory diseases including juvenile-onset rheumatoid arthritis, gouty arthritis

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

  • Grunenthal to market MSD’s pain drug Grunenthal to market MSD’s pain drug

    The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Immunotherapeutic wins US approval for severe form of childhood arthritis. The US FDA has cleared another indication for Novartis' fast-growing immunotherapeutic Ilaris, this time giving the nod to its use ... arthritis. Efforts to get a gouty arthritis

  • Novartis' Ilaris cleared for gouty arthritis in EU Novartis' Ilaris cleared for gouty arthritis in EU

    First biologic drug approved for condition in Europe. Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another ... The European Commission (EC) cleared llaris (canakizumab) for the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....